BTIG Research turned bullish on Orchestra Biomed Holdings Inc (OBIO), upgrading the stock to Buy and assigning a $10 price target, representing potential upside of 72.12% from Thursday's close.
PACCAR Inc (PCAR) has won the favor of RBC Capital Mkts's equity research team. The firm upgraded the shares from Sector Perform to Outperform and moved its price target to $150, suggesting 22.38% additional upside for the stock.
Simmons First National Corp (SFNC) received an upgrade from analysts at Keefe Bruyette, who also set their one-year price target on the stock to $26. They changed their rating on SFNC to Outperform from Mkt Perform in a recently issued research note.
BMO Capital Markets reduced its rating on Anglogold Ashanti PLC (AU) stock to Market Perform from Outperform and assigned the price target to $115.
RBC Capital Mkts analysts reduced their investment ratings, saying in research reports covered by the media that its rating for BioCryst Pharmaceuticals Inc (BCRX) has been changed to Sector Perform from Outperform and the new price target is set at $11.
Analysts at Evercore ISI downgraded Chewy Inc (CHWY) stock to In-line from Outperform, and the new price target is set at $25.